Castle Biosciences CFO sells 24,908 shares at $29.77

CASTLE BIOSCIENCES INC (CSTL) reported that its Chief Financial Officer, Frank Stokes, sold common stock in an open-market transaction.

Rhea-AI Filing Summary

CASTLE BIOSCIENCES INC (CSTL) reported that its Chief Financial Officer, Frank Stokes, sold common stock in an open-market transaction. On 2026-08-14, he sold 24,908 shares at a weighted-average price of $29.77 per share, executed in multiple trades between $29.71 and $29.97. Following this sale, he directly holds 35,177 shares of Castle Biosciences common stock.

Insider Trade Summary

Net Seller: 24,908 shares

Net Sell 1 txn

Insider Stokes Frank

Role Chief Financial Officer

Sold 24,908 shs ($742K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	24,908	$29.77	$742K

Holdings After Transaction: Common Stock — 35,177 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 24,908 shares Weighted-average sale price: $29.77 per share Post-transaction holdings: 35,177 shares +1 more

4 metrics

Shares sold 24,908 shares Common stock sold by CFO Frank Stokes on 2026-08-14

Weighted-average sale price $29.77 per share Average price for the 24,908 CSTL shares sold

Post-transaction holdings 35,177 shares Direct CSTL common stock held by CFO after the sale

Trade price range $29.71–$29.97 per share Range of prices for individual trades in the sale

Key Terms

weighted-average sale price, open market or private transaction, directly holds

3 terms

weighted-average sale price financial

"The price reported above reflects the weighted-average sale price."

open market or private transaction financial

"Transaction code S: Sale in open market or private transaction"

directly holds financial

"Following this sale, he directly holds 35,177 shares of common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CSTL report for Chief Financial Officer Frank Stokes?

Castle Biosciences (CSTL) reported that CFO Frank Stokes sold 24,908 shares of common stock on 2026-08-14. The weighted-average sale price was $29.77 per share, executed in multiple trades between $29.71 and $29.97.

How many CSTL shares did the CFO retain after the reported sale?

After the 24,908-share sale, CFO Frank Stokes directly holds 35,177 shares of Castle Biosciences common stock. This figure reflects his reported direct ownership immediately following the 2026-08-14 transaction.

At what price did the CFO sell Castle Biosciences (CSTL) shares?

The CFO’s Castle Biosciences share sale had a weighted-average price of $29.77 per share. The transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, according to the filing footnote.

How large was the recent CSTL insider sale by the CFO?

CFO Frank Stokes sold 24,908 CSTL shares in his latest reported insider transaction. These common shares were sold on 2026-08-14 at a weighted-average price of $29.77 per share, across multiple trades between $29.71 and $29.97.

Was the recent CSTL insider transaction executed in multiple trades?

Yes. The CFO’s sale of 24,908 CSTL shares was executed in multiple trades. The filing notes sale prices ranged from $29.71 to $29.97 per share, with a reported weighted-average sale price of $29.77.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stokes Frank

(Last) (First) (Middle)

C/O CASTLE BIOSCIENCES, INC.

1500 W. PARKWOOD AVE SUITE 400

(Street)

FRIENDSWOOD TEXAS 77546

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		S		24,908	D	$29.77(1)	35,177	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Frank Stokes, Attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)